Company Profile

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar (MBX-8025), is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The Company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation.

Employees

101

Sector

Biotechnology & Medical Research

More about the company

24-03-22	Gilead Sciences Completes $4.3 Billion Cymabay Acquisition	MT
24-03-22	CymaBay Therapeutics, Inc. Announces Board Changes	CI
24-03-21	CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Composite Index	CI
24-03-21	Gilead Sciences, Inc. completed the acquisition of CymaBay Therapeutics, Inc..	CI
24-03-21	CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Pharmaceuticals Select Industry Index	CI
24-03-21	CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P TMI Index	CI
24-03-21	CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Global BMI Index	CI
24-03-14	CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Biotechnology Index	CI
24-03-11	Gilead Sciences Says Antitrust Waiting Period for CymaBay Therapeutics Deal Expires	MT
24-03-04	CymaBay Says European Medicines Agency to Review Marketing Authorization Application for Seladelpar	MT
24-03-04	CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis	CI
24-02-28	CymaBay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
24-02-28	CymaBay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

24-02-20	Leerink Partners Downgrades CymaBay Therapeutics to Market Perform From Outperform, Adjusts PT to $32.50 From $26	MT
24-02-14	UBS Downgrades CymaBay Therapeutics to Neutral From Buy, Adjusts Price Target to $32.50 From $25	MT
24-02-14	LifeSci Capital Downgrades CymaBay Therapeutics to Market Perform From Outperform	MT
24-02-14	Piper Sandler Downgrades CymaBay Therapeutics to Neutral From Overweight, Adjusts PT to $32.50 From $33	MT
24-02-13	B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy on Heels of Announced Sale to Gilead Sciences, Raises PT to $32.50 From $29	MT

24-06-05	Long term efficacy and safety of open label seladelpar treatment in patients with primary biliary cholangitis (PBC): interim results for 2 years from the ASSURE study	PU
24-06-05	CymaBay Therapeutics : Assessment of PPAR-delta target engagement in mouse liver assessed by single nuclei sequencing following a single oral dose of seladelpar	PU
24-05-20	Gilead Sciences - Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis	AQ
24-03-25	Gilead Sciences Announces Completion of Acquisition of CymaBay	AQ
24-03-22	CymaBay Therapeutics : Acquisition/Asset Disposal - Form 8-K	PU

24-02-12	MÄRKTE USA/Wall Street nach Rekordjagd mit Gewinnmitnahmen
24-02-12	LATE BRIEFING - Unternehmen und Märkte
24-02-12	MÄRKTE USA/Wall Street nimmt Rekordjagd wieder auf
24-02-12	Gilead : sigla accordo per l'acquisizione di CymaBay per 4,3 mld$
24-02-12	MÄRKTE USA/Stagnation - Börse pausiert nach Rekordjagd

Manager	Title	Age	Since
Andrew Dickinson CEO	Chief Executive Officer	56	-
Deborah Telman SEC	Corporate Secretary	61	-

CymaBay Therapeutics, Inc. Stock

Stocks

CBAY

US23257D1037

Biotechnology & Medical Research

Latest news: CymaBay Therapeutics, Inc.

Analysts' recommendations: CymaBay Therapeutics, Inc.

Press Releases: CymaBay Therapeutics, Inc.

News in other languages: CymaBay Therapeutics, Inc.

Quotes and Performance

Managers and Directors: CymaBay Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/22/24	Sujal Shah	Issuer sale	Chief Executive Officer	4,432,651	3.8617%
3/22/24	Janet Dorling	Issuer sale	Director	161,010	0.1403%
3/22/24	Paul Quinlan	Issuer sale	Compliance Officer	753,230	0.6562%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYMABAY THERAPEUTICS, INC.	+0.03%	-.--%	-	-	3.73B
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+21.92%	+74.60%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+4.28%	+34.51%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+352.17%	+689.61%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+26.36%	+33.18%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+3.74%	+100.60%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+19.50%	28.53B
BIONTECH SE	+0.05%	-1.64%	-7.28%	-14.06%	24.34B
Average	-0.20%	-0.59%	+54.39%	+120.28%	43.39B
Weighted average by Cap.	+0.12%	-0.84%	+58.77%	+129.91%